Interactive Decision Support Tool on BsAb AE Management
Point-of-Care, Digital, Interactive Decision Support Tool (IDST) for the Prevention/Management of AEs During Treatment with BsAbs in MM

Released: January 06, 2025

Expiration: January 05, 2026

References

ASGCT. ASTCT Consensus Grading for CRS and ICANS. April 28, 2019. www.asgct.org/ASGCT/media/about/Approved-Neelapu_ASGCT_Workshop_042819.pdf. Accessed November 15, 2024.

Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130:2728.

Catamero D, Ray C, Purcell K, et al. Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Semin Oncol Nurs. 2024;40(5):151712.

Chari A, Krishnan A, Rasche L, et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-693.

Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 Study. Blood. 2023;142(Suppl1):1010.

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244.

Davi S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(10):2871.

Elranatamab [prescribing information]. New York, NY: Pfizer; 2023.

Faiman B, Mistry H, Rice M. Coordination of care for patients with heavily pretreated relapsed/refractory multiple myeloma receiving CAR T-cell and bispecific therapies. Updated December 5, 2023. Available at: https://resources.advancedpractitioner.com/multiple-myeloma/focus-on-bsabs/coordination-of-care-for-patients-with-heavily-pretreated-relapsed-refractory-multiple-myeloma-receiving-car-t-cell-and-bispecific-therapies/. Accessed October 16, 2024.

Farkas J. Hemophagocytic lymphohistiocytosis (HLH). June 5, 2024. Available at: https://emcrit.org/ibcc/hlh/#core_clinical_&_laboratory_findings_in_HLH. Accessed October 16, 2024.

Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295.

Hines MR, Knight TE, McNerney KO, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). 2023;29(7):438.

Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood. 2019;133(20):2212.

Khanam R, Faiman B, Batool S, et al. Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review. J Clin Med. 2023;12(17):5539.

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.

Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259-2267.

Ma X, Gong J, Yuan D, et al. Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1. J Clin Oncol. 2023;41(Suppl 16). Abstr 8041.

Mohan M, Chakraborty R, Bal S, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023;203(5):736-746.

Talquetamab [prescribing information]. Horsham, PA: Janssen; 2023.

Teclistamab [prescribing information]. Horsham, PA: Janssen; 2024.

US Department of Health and Human Services. Common terminology criteria for adverse events. Version 5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf. Accessed November 15, 2024.

Access to and use of this Interactive Decision Support Tool titled, “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for bispecific antibody therapy-related AEs in patients with R/R MM. The information provided is based on the latest prescribing information instructions and expert guidance of Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO; Melissa Pozotrigo, PharmD, BCOP; and Noopur Raje, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the Clinical Care Options material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content